EMEA-002146-PIP01-17-M04

Table of contents

Key facts

Invented name
Ibrance
Active substance
Palbociclib
Therapeutic area
Oncology
Decision number
P/0117/2022
PIP number
EMEA-002146-PIP01-17-M04
Pharmaceutical form(s)
  • Age-appropriate oral dosage form
  • Capsule, hard
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of Ewing sarcoma
Route(s) of administration
Oral use
Contact for public enquiries
Pfizer Europe MA EEIG

Tel. +44 1304 6466 07
E-mail: pip_enquiries@pfizer.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating